Novo Nordisk names new CEO amid share price slump and concerns over Wegovy, Ozempic sales

Danish pharmaceutical giant Novo Nordisk, known for its weight-loss drugs Wegovy and Ozempic, has named Maziar Mike Doustdar as its new chief executive, relying on an experienced company insider to make up ground lost to market rivals.

Mr Doustdar’s appointment came on Tuesday after the abrupt…